The clinically approved thrombolytic enzymes employed for treating cardiovascular disease are tissue plasminogen activator, streptokinase, urokinase, which will breakdown fibrin by converting plasminogen to plasmin, but all of these enzymes have some drawbacks like high price, shorter half-life, bleeding in the GI tract, allergic reaction, weak binding specificity and re-occlusion [9, 10]. This evidence concerns the gene PLG and cardiovascular disorder.